EUCOPE Resources / News - July 1, 2022
The objective of this survey is to capture the consequences of the Medical Devices Regulation (MDR) on innovative European companies, including those that have received significant government money. We expect that a contradiction could emerge between the massive investment done by the EU and Member… read more
Member Spotlight / News - June 24, 2022
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In June, we spoke with Julien Patris, Head of Policy – International Markets at Alnylam Pharmaceuticals. Julien Patris is Country… read more
EUCOPE Resources / News - May 10, 2022
As the science around genomics continues to evolve, advanced diagnostics technologies are delivering benefits to today’s patients while supporting future research and clinical development. However, beyond research programmes, many of these technologies are not reaching patients in clinical routine care in Europe. Patients’ health outcomes… read more
News - May 10, 2022
This article originally featured in PharmaBoardroom. You can find the original article here. EUCOPE’s Secretary-General Dr. Alexander Natz sees both opportunities and pitfalls with the EU HTA procedure, saying that the next three years will decide the crucial steps and whether the new procedure leads… read more
News / Partnerships in Focus - May 3, 2022
At EUCOPE, our commitment is to lead and engage in partnerships spanning the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve and healthcare systems overall. Through our Partnerships in Focus series, we’ll be highlighting different associates that we… read more
EUCOPE Resources - July 8, 2021
The complexities related to delivering some Advanced Therapy Medicinal Products (ATMPs) most likely will require highly specialized clinical expertise and infrastructures, which currently do not exist in all EU counties. Therefore, relocating or crossing borders often represent the only solution for many patients. A well-developed… read more
EUCOPE Resources / News / Press Releases - April 27, 2021
The objective of EUCOPE’s Advanced Diagnostics Working Group The Advanced Diagnostics Working Group is made up of diagnostics companies that have come together to ensure Europe will be able to draw benefit from the significant advances that have been made in genomic testing. The group… read more
News - January 19, 2021
The recent years have seen a number of high-end innovative therapies becoming accessible to patients in Europe. These products offer groundbreaking new opportunities to patients living with rare diseases or cancer, with the capacity of often one-time disease-modifying and potentially curative treatments. This new generation… read more
EUCOPE Resources / News / Press Releases - November 25, 2020
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the European Commission Communication on the Pharmaceutical Strategy for Europe. EUCOPE calls for a comprehensive Pharmaceutical Strategy… read more
News - May 29, 2020
As part of the collective response to COVID-19, a significant number of clinical trials are underway in an attempt to identify potentially effective COVID-19 treatments and bring them rapidly to patients. The EMA has published guidance documents on EMA initiatives for the acceleration of development… read more
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information